Bill J. Tawil Ph.D.

drtawil.jpg
Adjunct Associate Professor
Department of Bioengineering

4121F Engineering V
310-794-6140 | 310-794-5956 fax

 Education

  • B.S., University of California, Berkeley, 1986
  • M.Sc./Ph.D., McGill University, 1992
  • Postdoctoral Research Fellow, Massachusetts Institute of Technology, 1992-1996
  • MBA, California Lutheran University, 2006

Research Description

My research focuses on the use of biomaterials to deliver cells such as fibroblasts, keratinocytes, and stem cells. The biomaterials include fibrin and collagen. The resarch also focuses on generation synthetic materials coated with fibrin and collagen. The cell–biomaterial interaction is examined by studying the protein expression by cells incorporated in the constructs. The research also examines the biomechanical characteristics of the cell–biomaterials constructed over a period of time. The research so far shows that changing the concentration of fibrinogen, thrombin, or collagen in the final constructs influences the protein expression by the cells as well as the biomechanical characteristics of the constructs. The research also indicates that the environment within the constructs affects the mesenchymal stem cell differentiation into osteoblasts. 

Future questions under examination:
1. What is the optimal environment to deliver various types of cells?
2. What is the protein profile expression for various cells in different environments?
3. How do these cell – biomaterial constructs behave in In Vivo model?

Recent Papers

  1. Rahmany, M., Tawil, B., Hellman, K., Johnson, P., Van Dyke, M., and Bertram, T., “Bench to Business: A Framework to Assess Technology Rediness.  Tissue Engineering. Volume 19, Numbers 21-22: 2314-2317. 2013.
  2. Bertram, T., Tawil, B., Hellman, K., Johnson, P., Van Dyke, M., “Enhancing Tissue Engineering / Regenerative Medical Product Commercialization: The Role of Science in Regulatory Decision Making for Tissue Engineering / Regenerative Medicine Product Development. Tissue Engineering. Volume 19, Numbers 21-22, 2313. 2013.
  3. Linsley, C., Wu, B., Tawil, B., “The Effect of Fibrinogen, Collagen Type I and Fibronectin on Mesenchymal Stem Cells Growth and Differentiation into Osteoblasts. Tissue Engineering. Volume 19, Numbers 11-12, 1416-1423, 2013.
  4. Sese N., Cole M., Tawil B., “Proliferation of human keratinocytes and cocultured human keratinocytes and fibroblasts in three-dimensional fibrin constructs,” Tissue Eng Part A. 2011 Feb;17(3-4):429-37. Epub 2011 Jan 13.
  5. Chiu, C., Hecht, V., Duong, H., Wu, B., and Tawil, B., “Permeability of Three-Dimensional Fibrin Constructs Corresponds to Fibrinogen and Thrombin Concnetrations,” BioResearch Open Access, Volume 1, Number 1: 34-40, 2012.
  6. Bertram, T.A., Tentoff, E., Johnson, P.C., Tawil, B., Van Dyke, M., and Hellman, K.B., “Hurdles in Tissue Engineering / Regenerative Medicine Product Commercialization:  A Pilot Survey of Governmental Funding Agencies and the Financial Industry,” Tissue Engineering. Volume 18, Numbers 21-22, pp 2187-2194, 2012.
  7. Tawil, B., and Wu, B., “Three-Dimensional Fibrin Constructs in Tissue Engineering. Review. An Introduction to Biomaterials 2nd edition. Chapter 15: 249-262. Editors: J.O. Holilnger. Publisher: CRC Taylor & Francis.
  8. Hellman K.B., Johnson P.C., Bertram T.A., Tawil B., “Challenges in tissue engineering and regenerative medicine product commercialization: building an industry,” Tissue Eng Part A. 2011 Jan;17(1-2):1-3. Epub 2010 Sep 9.
  9. Johnson P.C., Bertram T.A., Tawil B., Hellman K.B., “Hurdles in tissue engineering/regnerative medicine product commercialization: a survey of North American academia and industry,” Tissue Eng Part A. 2011 Jan;17(1-2):5-15. Epub 2010 Sep 9.
  10. Mooney R., Tawil B., Mahoney M., “Specific fibrinogen and thrombin concentrations promote neuronal rather than glial growth when primary neural cells are seeded within plasma-derived fibrin gels,” Tissue Eng Part A. 2010 May;16(5):1607-19.
  11. Mogford J.E., Tawil B., Jia S., Mustoe T.A., “Fibring sealant combined with fibroblasts and platelet-derived growth factor enhance wound healing in exicsional wounds,” Wound Repair Regen. 2009 May-Jun;17(3)405-10.
  12. Duong H., Wu B., Tawil B., “Modulation of 3D fibrin matrix stiffness by intrinsic fibrinogen-thrombin compositions and by extrinsic cellular activity,” Tissue Eng Part A. 2009 Jul;15(7):1865-76.
  13. Cole M., Cox S., Inman E., Chan C., Mana M., Helgerson S., Tawil B., “Fibrin as a delivery vehicle for active macrophage activator lipoprotein-2 peptide: in vitro studies,” Wound Repair Regen. 2007 Jul-Aug;15(4):521-9.
  14. Catelas I., Sese N., Wu B.M., Dunn J.C., Helgerson S., Tawil B., “Human mesenchymal stem cell proliferation and osteogenic differentiation in fibrin gels in vitro,” Tissue Eng. 2006 Aug;12(8):2385-96.
  15. Ho, W. Tawil B., Dunn J.C., Wu B.M., “The behavior of human mesenchymal stem cell sin 3D fibrin clots: dependence on fibrinogen concentration and clot structure,” Tissue Eng. 2006 Jun;12(6):1587-95.
  16. Mana M., Cole M., Cox S., Tawil B., “Human U937 monocyte behavior and protein expression on various formulations of three-dimensional fibrin clots,” Wound Repair Regen. 2006 Jan-Feb;14(1):72-80. Erratum in: Wound Repair Regen. 2007 Jan-Feb;15(1):163.

Courses

  • Bioengr C147 / C247:  Applied Tissue Engineering: Clinical and Industrial Perspective (Winter Quarter)
  • Bioengr 298:  From Bench to Bedside:  How to Develop and Commercialize New Products (Spring Quarter)